MicroRNA 105-2 (MIR105-2)

MicroRNA 105-2 (MIR105-2, hsa-mir-105-2) is a short non-coding RNA molecule classified as a microRNA, located on human chromosome Xq28[2][4]. It is one of a small family (miR-105-1, miR-105-2, and miR-767)[2]. It regulates gene expression post-transcriptionally by binding to partially complementary sequences in target mRNAs, leading to translational repression or mRNA degradation[4][6]. MIR105-2 has context-dependent roles in cancer, functioning as either a tumor suppressor or an oncogene depending on tissue type and cellular context[2]. It is implicated in several cancer types, influencing processes such as tumor growth, metastasis, epithelial-mesenchymal transition, apoptosis, and chemoresistance. Upregulation or downregulation of miR-105 levels can serve as a prognostic or diagnostic biomarker in diseases such as multiple myeloma, triple-negative breast cancer, hepatocellular carcinoma, and gliomas[1][2][3]. Therapeutic targeting is still experimental, focusing on modulation of miR-105 activity rather than direct drug antagonism, and raises specific safety concerns typical of interventions affecting broad gene regulatory networks.

Other names

hsa-mir-105-2MIRN105-2mir-105-2MIR105-2

Not applicable (microRNAs themselves are gene regulators and not protein targets for binding by conventional drugs; therapeutic approaches are primarily based on modulation of miRNA levels using mimics, inhibitors, or antisense oligonucleotides)